Eli Lilly and Company (LLY) to Acquire Ventyx Biosciences

Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive agreement to acquire Ventyx Biosciences, Inc., which is a clinical-stage biopharmaceutical company that develops innovative oral therapies for patients with inflammatory-mediated diseases. Ventyx Biosciences, Inc. is in the process of developing a pipeline of small-molecule therapeutics for the treatment of inflammation across a range of disease states with highly unmet needs, including inflammatory disorders, cardiometabolic disorders, and neurodegenerative diseases.

The terms of the agreement entail that Eli Lilly and Company (NYSE:LLY) would acquire all the outstanding shares of Ventyx for $14.00 per share of common stock in an all-cash transaction, which equals an aggregate equity value of approximately $1.2 billion. Expected to close in H1 2026, the transaction is not subject to any financing condition, and is subject to approval of Ventyx stockholders and satisfaction of other customary closing conditions, which include regulatory approvals.

Eli Lilly and Company (NYSE:LLY) further reported that the transaction gained approval from the boards of directors of both companies, and that the purchase price payable at closing represents a premium of around 62% to the 30-day volume-weighted average trading price of Ventyx’s common stock ended on January 5, 2026.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.